Allarity Therapeutics (ALLR) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Allarity Therapeutics (ALLR) has outperformed TScan Therapeutics (TCRX) over the past year, losing 42.2% versus a loss of 88.5%. TScan Therapeutics is the larger company by market cap ($16.1 million vs $15.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLR | TCRX |
|---|---|---|
| Share price | $0.995 | $0.2381 |
| Market cap | $15.83M | $16.14M |
| 1-day change | +1.33% | +4.34% |
| YTD return | -9.08% | -77.18% |
| 1-year return | -42.24% | -88.47% |
| 5-year return | — | -96.62% |
| EPS (TTM) | $-0.79 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.84 | $2.57 |
| 52-week low | $0.769 | $0.224 |
| Distance from 52-week high | -45.92% | -90.74% |
| Analyst consensus | none | hold |
| Avg. price target upside | +1005.53% | +319.99% |
| Average volume | 90.75K | 783.59K |
| Shares outstanding | 15.91M | 63.50M |
| Employees | 7 | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLR has outperformed TCRX by 46.2 percentage points over the past year.
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
ALLR vs TCRX FAQ
Which is bigger, Allarity Therapeutics or TScan Therapeutics?
TScan Therapeutics (TCRX) is larger, with a market capitalization of $16.14M compared with $15.83M for Allarity Therapeutics (ALLR).
Which stock has performed better over the past year, ALLR or TCRX?
ALLR returned -42.24% over the past 12 months, compared with -88.47% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are Allarity Therapeutics and TScan Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Allarity Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for TScan Therapeutics.